Furthermore, in primary liver cancer, Lowdon RF et al. identified a somatic mutation (chr4:81,187,908; A > T) in the FGF5 promoter region, which generates a new MYC binding site and enhances FGF5 expression [84]. Here, FGF5 is linked to liver cancer.